In the healthcare and pharmaceutical sector, the importance of investment and financing is self-evident. In recent years, with changes in the global economic environment and fluctuations in capital markets,Traditional financing and business collaboration models can no longer meet the needs of domestic biotech companies.. In particular, in 2023, the global healthcare industry’s ability to attract capital further contracted, with total financing falling back to 2019 levels.Data shows that the total amount of domestic and overseas financing in the pharmaceutical field in 2021 exceeded137.4 billionU.S. dollars, while in 2023 there were only53.6 billionaround USD, with a decline of over60%This shift could spell “death” for companies with cash reserves insufficient to last more than five years, as they may be doomed the moment the “winter” sets in. Compounded by difficulties in securing external financing, over 30% of enterprises have been forced to cease operations.
ImageSource:ArteryOrangeDatabase
Against this backdrop, many companies have experienced cash flow exhaustion due to their inability to secure financing and investment channels, thereby hindering business development. However, some enterprises have managed to turn the tide and revive through fundraising. Data shows that in 2023, Chinese innovative pharmaceutical companies achieved remarkable results in business development (BD) transactions for their projects,228 New Drug BD Deals Secured RMB 26.7 Billion in Upfront Payments, Surpassing Total IPO Fundraising for the First Time. This indicates that,Despite the challenging financing environment, some companies have managed to find opportunities for survival and growth through fundraising and business development (BD) transactions.。
Figure: Number of Domestic Biopharma License-in, License-out, and Domestic Transactions from 2019 to 2023
Image source: White Paper on Trends and Strategies for the Global Expansion of China’s Innovative Drugs and Medical Devices in 2024
Figure: Total Value of Domestic Biopharma License-in, License-out, and Domestic Transactions in China (2019–2023) (USD billion)
Image Source: White Paper on Trends and Strategies for the Global Expansion of China's Innovative Drugs and Medical Devices in 2024
The “union” between high-quality projects and investors is akin to the tale of the swift horse and its discerning master, a serendipitous encounter whereVCBeatHosted by2025 VBEFThe conference is all set. Centered on innovation and in-depth resource connectivity, the conference providesInvestment and Financing Opportunities, Business Development (BD) Collaboration Opportunities, Industrial and Supply Chain Transaction Opportunities, Finished Product Trading Opportunities, Overseas Market Expansion Opportunities, creating more "win-win" stories between talented individuals and their discerning mentors.
3000+ Capital and BD Resources Converged
Building a Golden Bridge
A healthy and positive industrial ecosystem serves as the fertile ground for innovation. Since its establishment, VCBeat has covered90%The aforementioned investors in China's healthcare and pharmaceutical sectors,80%The aforementioned investors in China’s healthcare and pharmaceutical sectors have participated in the Future Healthcare & Pharma Top 100 List and the VBEF Conference. Over the past decade,VCBeat reported9927# Homegrown Innovative Enterprises，70% First-Launch Rate(Data as of the end of 2023).
2025 VBEF Conference: VCBeat will leverage its extensive investment, financing, and business development resources to create abundant opportunities for collaboration and communication among exhibiting companies, building an efficient matchmaking platform that brings together3000+Decision-makers from leading domestic and international investment institutions, industrial investors, and government industrial guidance funds, attracting over1,000 peopleMNCs and leading Chinese healthcare and pharmaceutical companies seeking business development (BD) collaborations for high-quality projects, products, and technologies, accelerating the exchange and cooperation on the most distinctive new technologies, new products, and new ecosystems in China.
Selected Investment Institutions from Previous VBEF Conferences
Selected MNCs and Leading Chinese Enterprises from Previous VBEF Conferences
10+ VC & BD Forum Events
Igniting the Spark of Collaboration
StationAt the threshold of a new era of revolutionary change, and in the face of the surging dynamics in cutting-edge and high-profile sectors, enterprises and venture capital firms need to pursue deeper integration and mutual engagement.Over the past decade, VCBeat has hostedNearly 100 sessionsInvestment Roadshows, BD Salons, and Technology Transfer Conferencesa series of investment, financing, and business development forums, focusing on cutting-edge applied research, the translation of scientific and technological achievements, and product collaboration models, effectively bringing together10000+MNCs, Investment Institutions, and Innovative Enterprises.
Over the past eight years, the VBEF Conference has successfully facilitated nearly 1,000 instances of in-depth collaboration among multinational corporations (MNCs), investment institutions, and innovative enterprises. In 2025, the VBEF Conference will continue this momentum, driving the efficient integration of investment and innovation within the healthcare, pharmaceutical, and health industries.
2025 VBEF ConferenceThe event will be held on-siteFuture Healthcare Top 100 Conference: Fund Partners Summit, China NewCo Summit, Annual Meeting of Entrepreneurs from Renowned Investment Institutions, MNC China Innovation Practice Ecosystem Co-Creation Conference, CGT Venture Capital and BD New Opportunities Forum, RNA Venture Capital and BD New Opportunities Forum, MNC China Innovation Ecosystem Exhibition, Medical and Pharmaceutical Innovation Project Roadshow, Medical Device Scientific Research Achievement Transformation Roadshowand over 10 other related events. Through on-site forum speeches, project roadshows, exhibitions and exchanges, and one-on-one negotiations, we help exhibiting companies with clear needs for investment, financing, and business development (BD) partnerships to precisely connect with potential investors, jointly exploring new blue ocean markets.
Innovative Release,Amplifying the Voices of Outstanding Enterprises
Established in 2015,Top 100 Future Healthcare Companies ListYesChina's First Innovation Healthcare Ranking for Private Companies, aiming to select Chinese innovators in healthcare who truly represent the future of medicine, identify the core forces driving China’s future healthcare industry, and promote innovative transformation in the health and medical sector. After nine years of practice and exploration,“The Top 100 Future Healthcare Companies” selection has received strong support and recognition from numerous institutions and enterprises.，A large number of investment institutions participate in it every year., cumulative number of listed companies3964Home, Rankings/Awards Announcements243Zhang has become a bellwether for investment in the healthcare sector, steering the development and investment trends in China’s healthcare innovation landscape both currently and in the foreseeable future, while providing valuable references for follow-on financing by innovative enterprises.
Furthermore, VCBeat annually releases a Growth Report on the Top 100 Companies, based on that year’s Future Healthcare 100 list, providing a comprehensive analysisChina Innovative Medical Services List, China Innovative Medical Devices List, China Innovative Digital Health List, China Innovative Biopharmaceuticals ListAnnual performance and historical trends of companies featured across the four rankings, analyzed across dimensions such as valuation, founding date, financing rounds, geographic distribution, and key sectors. By analyzing the companies listed in the Future Healthcare 100, we aim to summarize patterns of corporate growth and industry evolution, providing valuable insights for healthcare enterprises and entrepreneurs.
Innovative Case Studies from the Top 100 Enterprises Growth Report
See You in Suzhou Next Year
New Exhibition Layout Unveiled
The 2025 VBEF Conference, centered on innovation and in-depth resource connectivity, provides for entities across the entire Chinese healthcare and pharmaceutical industry chainInvestment and Financing Opportunities, BD Partnership Opportunities, Industrial and Supply Chain Transaction Opportunities, Finished Product Trading Opportunities, Overseas Market Expansion Opportunities. During each conference, the Top 100 List of Future Healthcare and Pharmaceuticals will be released, attracting tens of thousands ofMedical Devices, Innovative Pharmaceuticals, Biomanufacturing, Life Science Instruments, Healthcare ServicesProfessionals from upstream and downstream enterprises in the industry chain, as well as representatives from universities and research institutions, will attend the event.
May 8–10, 2025, the 2025 VBEF Conference will expand to30000+square meters, hand in hand500+Domestic and international exhibitors,1000+Innovative Products Centered on the Healthcare and Pharmaceutical Sector40+Hosting forums and events in popular innovative sectors to attract20+National and Regional20000+Global and Domestic High-End Attendees, Gathered TogetherSuzhou International Expo Center。
Exhibitor/Visitor Inquiry
Media and Business Cooperation
Ms. Huang 13801260803
